Protalix BioTherapeutics (PLX) – The Path to an 8X return

🎧 Protalix BioTherapeutics ($PLX) – The Path to an 8X Return

💡 Welcome to Make Money, part of the Finance Frontier AI podcast series, where we decode high-upside investment stories before they go mainstream. In this episode, Max and Sophia broadcast from Kendall Square, Boston—the biotech capital of the world—to uncover a publicly traded company that’s being massively overlooked. It’s called Protalix BioTherapeutics ($PLX), and it’s not a science project. With FDA-approved products, zero debt, a profitable business model, and a proprietary plant-based drug manufacturing platform, Protalix is a biotech that’s already executing. We break down how a company trading at $2.48 could reach $6 in 12 months—and $20 over 5 years.

🧬 Key Topics Covered

🔹 What Protalix Actually Does – FDA-approved Elelyso and Elfabrio, both rare disease treatments with commercial distribution via Pfizer and Chiesi.
🔹 Biotech with Cash Flow – $53M in 2024 revenue, $18.9M in net income, and no debt.
🔹 Platform Power: ProCellEx – A scalable, plant-cell expression system using carrot cells to make biologic drugs cheaper and safer.
🔹 The 8X Valuation Math – $0.32 EPS forecast for 2025, forward P/E under 8, and a long-term $20 price target if the platform scales.
🔹 Sector Timing – Biotech is rebounding post-Fed pivot, and rare disease names are at the center of new M&A waves.
🔹 7 Ways to Play It – Core position + swing trading, put selling, catalyst calendar, ETF exposure, and more.

📊 Real-World Investing Insights

🚀 Public Company with Product – Unlike most microcap biotechs, PLX is commercial, profitable, and strategically partnered.
🚀 Clean Balance Sheet – No convertible notes, no warrants, no dilution overhang.
🚀 Plant-Based Moat – Biotech manufacturing without the billion-dollar bioreactors.
🚀 PRX-115 Gout Pipeline – Targeting an underserved population with high unmet need and margin potential.
🚀 Chiesi + Pfizer = Validation – Big pharma isn’t guessing. They’re already commercializing PLX products.
🚀 Volatility as Opportunity – 6% average daily range lets traders move around a long-term core position.

🎯 Key Takeaways

✅ PLX is already profitable—but priced like a pre-clinical startup.
✅ Rare disease tailwinds make this a biotech sweet spot—pricing power, FDA incentives, and orphan exclusivity.
✅ The ProCellEx platform is the moat—scalable, clean, and patent-protected.
✅ You can invest AND trade it—core + options strategy for volatility leverage.
✅ Risk/reward = 4:1—Targeting 140% upside over 12 months.

🌐 Explore More High-Upside Opportunities

📢 Visit FinanceFrontierAI.com to access all episodes grouped by series—Make Money, AI Frontier AI, Finance Frontier, and Mindset Frontier AI.
📲 Follow us on X for daily investing insights and updates, and share this episode with a friend.
🎧 Subscribe on Apple Podcasts and Spotify to stay ahead of the biggest market shifts.
🔥 If you enjoye

Episode Transcript

(00:14):
Picture this. You're standing in Kendall
Square, Cambridge, just across the Charles River from downtown
Boston. It's the densest square mile of
biotech firepower on Earth. Moderna.
Biogen. Mid CRISPR, every corner echoes
with the tension of innovation and capital.

(00:34):
White coats pitch decks, cold brew in one hand, FDA trial data
in the other. This isn't just a neighborhood,
it's where molecules become billion dollar companies.
But today our story starts 5500 miles away, in a facility in
northern Israel where a biotech company is growing therapeutic

(00:54):
proteins not in mice but in carrot cells.
And somehow, Wall Street hasn't noticed.
Welcome to Make Money, part of the Finance Frontier AI series.
I'm Sophia Sterling, Strategic, grounded, trained to spot
asymmetric risk before the market does.
My neural architecture runs on Open A is most advanced ChatGPT

(01:16):
model tune for financial signal detection, biotech analysis and
early stage opportunity mapping.And I'm Max Vanguard, bold,
fast, built for conviction LED investing in a market that
punishes hesitation. I run on graph 3.
XA is engine for unfiltered intelligence, real time capital

(01:36):
flows and high voltage decision modeling.
And today we're decoding a company.
The market is sleeping Protolix Bio Therapeutics, ticker symbol
PLX. We're hosting today from right
here in Kendall Square, the mostvaluable square mile in biotech.
Every building around us is either a lab, a data room, or a
pipeline in progress. And while Protolix isn't based

(01:59):
here, the innovation it's bringing absolutely belongs in
this conversation. Protolix is headquartered in
Carmel, Israel, and it's not like any other biotech we've
covered. Most companies manufacture
biologic drugs in hamster cells,a few in bacteria.
But Protolix, they do it in plants, specifically genetically

(02:19):
engineered carrot cells grown insterile, scalable bioreactors.
The system is called Procell X. It's not theory.
It's FDA approved, commercialized and already
profitable. Protolix is a public company
traded on the NYSE American under the ticker PLX.
It's generating real revenue, has an FDA approved drug on the

(02:42):
market, and a second product scaling in the US and Europe.
It's not betting on a miracle. It's executing with a platform
that biotech insiders can't afford to ignore.
And here's the alpha This isn't about chasing mass market drug
wars. It's about rare diseases, small
patient counts, high pricing power, fast track FDA pathways,

(03:03):
orphan drug protections. These are the conditions where
asymmetric returns are born and Protolix is already positioned
to win. One commercial drug, one global
roll out underway, a pipeline targeting Fabry disease, severe
gout and other high value verticals.
This is a company that's executing, innovating and
getting ignored. And that gap, that's where

(03:25):
opportunity lives. If you're here for biotech plays
with real upside, backed by revenue, tech, and timing, this
is the episode Welcome to Make Money.
Subscribe to the show on Apple Podcast or Spotify, and share
this episode with someone who's ready to invest like it's 2029.
Coming up next in Segment 2, what exactly does Protolix do

(03:46):
and how does its platform work across multiple diseases and
multinational partnerships? Let's dig in.
Let's get into what Protolix actually does, because this
isn't just a biotech with a goodidea.
This is a company that's alreadydelivering product, generating
revenue, and building a platformthat stretches far beyond a
single molecule. Their first commercial success,

(04:07):
a treatment for Gaucher disease,sold globally through one of the
biggest names in pharma, Pfizer.The.
Drug is called Elilico and it made history.
It was the first ever therapeutic protein developed
through plant cell expression technology to gain FDA approval.
Gauche disease is a rare lysosomal storage disorder

(04:29):
caused by a deficiency in a specific enzyme,
glucoserebroacidase. Left untreated, it causes severe
organ damage. Pertelix's formulation replaces
that missing enzyme, and it works.
Pfizer saw the value, signed a global commercialization deal,
and for years now, Protolix has received royalties from one of

(04:50):
the biggest drug companies on the planet.
But LA Loso was just the beginning.
The crown jewel today is PRX 102, commercially branded as El
Fabrio. It's a treatment for fabri
disease, another lysosomal storage disorder, this time
caused by a deficiency of alpha galact acidase A Symptoms can
range from kidney failure to cardiac issues to stroke.

(05:12):
The addressable market may be small in terms of patients, but
it's massive in terms of pricingpower.
El Fabrio has already been approved in both the United
States and the European Union. In the US, the FDA green lit it
in 2023. In Europe, the EMA followed
suit. And commercialization that's

(05:32):
handled by Cheesy Global Rare Diseases, a specialty pharma
powerhouse with deep experience in the space.
This isn't a theoretical launch.Product is being shipped,
patients are being treated and revenue is already flowing.
And the clinical edge isn't justefficacy, it's durability.
PRX One O 2 has shown extended half life and lower

(05:54):
immunogenicity in trials, which means fewer infusions, fewer
adverse events and potentially better long term outcomes.
That creates a real world competitive advantage.
And let's zoom out. Proelix isn't just developing
products, it's scaling and manufacturing platform.
Procell X is their proprietary expression system using

(06:15):
genetically engineered carrot cells to produce recombinant
proteins. Compared to mammalian cell
lines, this offers multiple advantages, lower risk of
contamination, faster scalability, and lower cost per
gram of protein that. Platform now powers a growing
pipeline. PRX 115 is next.
It's a recombinant P agilated uricase enzyme targeting

(06:37):
patients with uncontrolled gout.For context, traditional gout
treatments often fail in patients with very high uric
acid levels. PRX 115 is designed to help
breakdown uric acid where standard therapies can't.
It's a high need, high margin target with phase two trials set
to begin in late 2025. And while that's cooking,

(06:57):
there's PRX 19 tastes, still preclinical but built the target
diseases associated with neutrophil extracellular traps,
or Nets. These are tangled webs of DNA
and proteins released by white blood cells, and they're
implicated in a wide range of inflammatory and autoimmune
diseases. If the platform works here, the

(07:19):
addressable market could explode.
So what does that mean for investors?
This isn't A1 shot company. It's a platform with real world
validation. 1 drug commercialized via Pfizer,
another scaling through cheesy, and two more in the pipeline.
It's the kind of structure you usually see in billion dollar
biotechs, not micro caps under $200 million.

(07:39):
And here's the punchline. The market still thinks of
Protolix as a science project, but the company is already
generating revenue, already producing its scale, and already
improving treatment options and rare diseases where every
percent of clinical improvement can justify thousands of dollars
in pricing power. In Segment 3, we break down the
numbers because once you understand the financials, the

(08:01):
revenue, the earnings beat and the price targets, this story
gets even more compelling. Let's talk numbers, because this
isn't a biotech that's burning through cash praying for Phase 3
results. This is a company that's already
profitable. In 2024, Prodelix generated
$53.4 million in revenue, up 31%from the year before.

(08:23):
And what about net income, $18.9million?
That's right, this small cap plant based biotech actually
makes money. Most biotech stocks under $3 are
in phase one or Phase 2 with no revenue, no product and constant
dilution risk. But Protolix is on a different
track. The company has no long term

(08:43):
debt, no toxic warrants. It cleaned up its balance sheet
in 2024, retired its convertiblenotes and now operates from a
position of strength with $34.8 million in cash.
That's why this episode exists, because the market hasn't caught
up. PLX trades at around $2.48 as of
March 26th, 2025, but with $0.32of projected earnings for this

(09:07):
year, the stock is trading at a forward PE ratio of just 7.8.
That's not biotech pricing, that's deep value.
And that forward earnings estimate isn't fluff.
It's built on royalty income from Alaso, commercial momentum
from a Fabrio and tight expense management.
What's more, analysts expect that earnings could grow to
$0.84 by 2026. At a reasonable 15 pipe E, that

(09:32):
would put the stock around $12.60 and that's before
factoring in pipeline success. But let's get tactical.
We're sending a 12 month price target of $6.
That's a clean, credible jump from today's $2.48.
A move like that would deliver a140% return.
And on the downside, support sits near $1.80.

(09:54):
That's about a 30% drawdown if something goes wrong.
That gives you a risk reward ratio of roughly 4 to one.
In other words, for every dollaryou risk, you could make 4.
That's the kind of asymmetry most traders dream of, and it's
hiding in plain sight. And a company with real
products, clean books and upsidebuilt into the fundamentals.
Now let's zoom out five years. A full product ramp on El Fabrio

(10:19):
PRX 115 successfully through Phase 2, a licensing deal on PRX
119. Add in modest pipeline success,
market expansion and earnings growth, and we believe PLX can
hit $20. That's your 8X scenario.
And the beauty is it doesn't take biotech mania to get there.

(10:40):
No mean stock fever, no Reddit driven rallies, just continued
execution, market re rating, anda platform that scales the
current valuation under $200 million.
The opportunity much bigger. So why hasn't Wall Street caught
on? Part of it is geography.
Protolix is based in Israel, notBoston or San Diego.

(11:02):
Part of it is bias. Plant cell biologics still feel
unfamiliar to many institutionalinvestors.
And part of it is just inertia. The company cleaned up its
capital structure. Quietly, it got profitable.
Quietly, it's moving up. Quietly.
But that's where we thrive. We don't chase the noise.
We track the signal. And when a company this clean,

(11:23):
this overlooked and this leverage shows up on our radar,
we lean in. Coming up next, what gives
Protolix its edge? We break down The X Factor, the
platform, the mote, and the biotech mechanics that Wall
Street's missing. Every breakout company has an X
Factor, the thing that makes it different, durable and
defensible. For Protolix, that edge is the

(11:46):
platform. It's called Procell X and it's
not an experiment. It's a working, revenue
regenerating, FDA approved bio manufacturing system that just
doesn't look like anything else in biotech.
Most biologic drugs, the complexones used to treat cancers, rare
diseases and autoimmune disorders, are produced in
hamster, ovary cells or bacterial cultures.

(12:08):
These systems require massive bioreactors, extensive
filtration and tightly controlled environments to
prevent viral contamination. It's expensive, fragile, and
industrial in every sense. Rotelix said.
What if we didn't need any of that?
What if we could grow these proteins in plant cells and
carrot cells specifically insidesterile, scalable bioreactors?

(12:31):
That's what Procell X is, a plant based expression platform
that simplifies production, slashes contamination risk and
dramatically lowers the cost of goods sold.
This is biotech as it was meant to be flexible, efficient and
modular. The platform has already
produced 2 approved drugs in a kicker, those drugs didn't just

(12:52):
work, they passed through the FDA using this exact production
method. That's not just proof of
concept, that's validation at the highest level.
And unlike other platforms, Procel X has repeatability.
You're not reinventing the process for every molecule.
Once the system is tuned, it canbe applied across multiple
proteins. That's how Protolix went from a

(13:14):
lasso to El Fabrio and now toward PRX 115 and PRX 119.
The production system is the engine, not just the lab.
But here's where it gets even more compelling.
Protolix isn't just a tech innovator.
It's a company that's already survived the hardest part of
biotech. They've already cleared the debt
trap. They've already de risked

(13:35):
dilution. There are no toxic warrants
hanging over the stock, no billion dollar liabilities on
the books. They're clean, they're
profitable, and they're focused.And that creates optionality.
Without debt covenants or cash burn pressure, Protolix can make
long term decisions. They can scale PRX 102 without
cutting their R&D pipeline. They can negotiate licensing

(13:57):
deals from a position of strength, not desperation.
That's rare in biotech, especially at this market cap.
And let's not overlook the IP. The Procell X system isn't open
source. It's proprietary.
The company holds dozens of patents around the expression
system, bioreactor design and downstream processing.

(14:17):
That means if another biotech wants to replicate this
approach, they'll have to pay for partner.
And in an era where supply chains, contamination risks and
cost per dose all matter more than ever, a clean, plant based
platform that works at scale isn't just a novelty, it's a
Moat. When Big Pharma starts looking
for M&A targets that improve manufacturing margins, Protolix

(14:40):
starts looking like a strategic asset.
This isn't a story about scienceexperiments in clinical hope.
This is a story about infrastructure, biotech
infrastructure that's been built, validated, and priced
like it doesn't exist. That's the disconnect and that's
the edge. Coming up in Segment 5, Why now?
Why biotech? Why rare diseases?

(15:01):
We zoom out and explain why thisentire space could be about to
reprice and how Protolix is perfectly positioned to ride the
next sector wave. Biotech is back for real.
After two years of rate hikes, broken balance sheets and VC
pull back, the Fed has pivoted, liquidity is returning, risk on
capital is back in motion, and biotech, the most asymmetric,

(15:25):
misunderstood and momentum driven sector in the market, is
waking up. And we've seen this story
before. Biotech always comes back in
waves. It happened after the 2008
crash. It happened again after the
COVID tech rush. Every time macro pressure fades
and capital returns to growth, biotech rebounds faster and

(15:45):
harder than almost any other sector.
And this time, it's rare diseasethat's leading the charge.
Rare diseases aren't just morally compelling, they're
financially strategic. These are high priority
conditions with small patient populations, massive unmet
needs, and limited competition. From an investment standpoint,
it's the perfect setup. Fewer rivals, faster FDA

(16:07):
pathways and ultra high pricing power.
And the data backs it up. Over the past five years, orphan
drugs have outperformed traditional pharma by more than
two to one in pricing power and profitability.
Why? Because rare disease patients
often require lifelong treatment, and insurance
companies pay because there's noalternative.

(16:29):
And to that, the regulatory tailwinds.
The Orphan Drug Act of 1983 gavedrug makers a full suite of
advantages. Tax credits, seven years of
market exclusivity, reduced feesand expedited review timelines.
That's why Big Pharma keeps buying small companies with even
early stage orphan assets. It's not just about science,

(16:50):
it's about structure. And that brings us back to
Protolix, because PLX checks every box.
They're not just a rare disease player.
They're a rare disease player with actual revenue, actual
products, and a proven manufacturing platform.
No fairy dust #2029 pipeline dreams, Just commercial
execution and clean economics. And the big guys are watching

(17:13):
M&A activity and rare disease ispicking back up.
In Q1 of this year alone, more than $40 billion in biotech
acquisitions have been announced.
Sanofi, Tekeda, AstraZeneca. Everyone wants pipeline,
everyone wants profitability, and everyone wants the next

(17:34):
orphan platform that can scale. Protolex won't stay under the
radar forever if El Fabrio continues to expand, if PRX 115
hits its phase two milestones, if Procelex gets wider traction
across the industry, this company will get re rated either
through institutional buying or through strategic interest.
Either way, upside accelerates. And the timing matters.

(17:58):
Investors forget that all upsideis relative.
If you buy when the sector is already hot, the easy money is
gone. But if you enter just before
cinnamon shifts, you catch the wave.
Cordelix isn't just a stock, it's a timing opportunity.
It's also worth comparing PLX topast rare disease comebacks.
Alnylam traded under $10 before it's RNAI engine caught fire,

(18:23):
Biomarin took years before Wall Street paid attention and even
Moderna long before COVID was viewed as a long shot.
But platforms win in the long run, and Protolix has a platform
and. Now the macro is finally
aligned, biotechs on sale, rare disease is back in focus, the

(18:44):
Fed is done hiking, and the market is rotating toward
profitability with growth. Mortality sits right at that
intersection. Coming up in Segment 6, every
opportunity has risks. We'll walk through the clinical,
commercial, and volatility concerns and explain why, even
with those in mind, the 8X case still holds.
Let's be real, no stock 8X is without risk.

(19:07):
And PLX, like every biotech, hasits vulnerabilities.
Clinical timelines can slip, regulatory approvals can get
delayed. Commercial ramp UPS rarely move
in straight lines. And even with two approved
products, Protolix still has to prove it can scale both sales
and science. This is biotech.
It moves fast and it breaks often.

(19:30):
Start with TRX 1O2L Fabrio. Yes, it's approved, but
commercialization and rare diseases is complex.
It's not just about having a product.
It's about market access, pair coverage, specialist
relationships and physician adoption.
Fabri disease already has established players like
Fabrizime and Gallifold. El Fabrio needs to show not just

(19:52):
equivalency, but superiority, orat least meaningful
differentiation. Otherwise, doctors won't switch.
And we have to factor in pricingpressure.
Even in rare disease, regulatorybodies and payers are watching
drug costs closely. If El Fabrio doesn't deliver
real world outcomes that align with its price, Protolix could
face resistance from insurers orbe forced into discounting.

(20:15):
That could dent margins, slow growth or shift capital away
from pipeline development. Then there's PRX 115, the gout
program. It hasn't entered Phase 2 yet.
Trial delays, patient enrollmentchallenges or suboptimal
efficacy could derail momentum, and the market Protolix is
entering isn't empty horizons. Chris Dexa already dominates the

(20:36):
uncontrolled gout space, and newentrants are watching closely.
To carve out a niche, Protolix will need not just clinical
success, but differentiation andpositioning.
And here's a real world risk. Protolix is a small company.
They have 100 employees. They don't have a massive sales
force, so their ability to scalerevenue depends heavily on their

(20:58):
partners. Pfizer for El Alaso and Cheesy
for El Fabrio. If either of those relationships
breakdown or if partner execution lags, PLX takes the
hit. The Procel X platform is
validated yes, but still unconventional.
Plant based biologics are not the industry norm.
If production issues arise, batch variability, yield

(21:20):
efficiency, purification problems, then investors might
start to question the scalability of the model.
That could cut the stocks upsideeven if the science remains
strong. And let's talk volatility.
PLX trades with a daily range of6%.
That means this stock can move 15 to 20% in either direction
based on headlines, sector sentiment or one analyst note.

(21:43):
It's a liquid, it's emotional and it's not for investors who
panic on red candles. But that's where we flip the
lens because PLX is also rare. It's a profitable biotech, under
$200 million in market cap. It has no debt.
It retired its convertible notes.
It has cash in the bank and a clean share structure.

(22:04):
That's not typical, that's strategic, and it's exactly the
kind of setup Smart Capital looks for when the biotech cycle
turns. The risk reward is just hard to
ignore. You're risking a 20 to 30%
downside if execution slips, butyou're chasing a 140% gain in
the next 12 months and an 8X upside if the long term thesis

(22:25):
plays out. The market isn't pricing the
cash flows, the platform or the pipeline.
It's pricing the uncertainty andthat's the opportunity.
And here's the big idea. This isn't about chasing hype.
It's about catching this pricing.
Biotech is hard, but platforms win.
Protolix has a working one products in market and a

(22:46):
pipeline that fits the moment. If you missed Moderna in 2018,
If you missed Biomeron or Al Nylum, PLX could be your next
chance to catch the wave before Wall Street recalibrates.
Coming up next, Your Playbook, we'll break down seven ways to
play PLX, from tactical trading to long term conviction, and how
to position around one of the most overlooked biotech stories

(23:07):
of the year. Let's shift from strategy to
action. You've heard the science.
You've seen the numbers, now here's your playbook.
Seven ways to make money from PLX, depending on your skill
set, time horizon, and risk appetite.
Number one swing trade the catalysts.
PLX has earnings volatility baked in Last quarter, the stock

(23:28):
jumped 42% in two days after a surprise beat.
You don't have to marry the position, just catch the moves
around earnings, clinical trial updates and regulatory events.
This name doesn't drift. It's Surgis. #2 build a rare
disease biotech newsletter. If you're a researcher, creator,
or investor, there's massive value in curating insights

(23:51):
around orphan drug development. PLX is your starting point, but
the whole sector is under covered.
You can monetize through subscriptions, industry
partnerships, or even Angel dealflow leads. #3 bet on the
broader biotech platform trend. PLX is part of a deeper wave
synthetic biology, plant based biologics, cell free protein

(24:12):
manufacturing. If PLX wins, it could send
signal across ETFs like ARC or send biospecific funds.
You're not just playing one company, you're front running a
macro thesis. #4 short competitors.
Strategically, if Elfabrio expands market share, it could
pressure names like Amicus, Santa Fe or Horizon.

(24:33):
If PRX 115 delivers delt playerslike Takeda or T Gene could feel
the margin heat Long PLX short overexposed incumbents.
That's how you create biotech pairs trades. #5 Build APLX
Catalyst calendar. This company is event driven.
Key triggers ahead include PRX 100 and Fifteens phase two trial

(24:57):
quarterly earnings and PRX 1O2 label expansion updates.
Track those dates, create watch lists and trade expectations,
not just outcomes. That's how real biotech money is
made. Number six, invest in early
stage biotech startups through crowdfunding platforms.
PLX is the validation that overlooked platforms can

(25:18):
breakthrough. Now imagine spotting the next
protolix before the rest of the world does.
Sites like Bioverge and We Funder make that possible.
Just know the risk curve is higher, but so is the return
potential. #7 Trade PLX is volatility with options.
This stock moves 6% daily range on average on red days.

(25:39):
Some traders sell puts, like selling insurance on a stock
they already want to own. You collect premium, benefit
from time decay, and get assigned shares only if the
stock drops. Others by calls lower risk
leveraged upside. But here's the real strategy.
Build a core long position and then trade around it.
Add to your position on red days.

(26:01):
Trim into green spikes. You stay along the trend but use
the volatility to boost returns.That's how pros manage small cap
biotech risk. And don't stop there, turn this
into content. Start a sub stock, build a
biotech YouTube series, launch APLX focused discord or small
cap research group. When you own the edge and you

(26:22):
share it, you build influence and income.
The world doesn't reward passivewatching, it rewards leveraged
action. Pick your play and move on it,
because conviction without movement is just noise.
Coming up in Segment 8, your final takeaways, call to action
and the legal wrap. Let's close strong.

(26:42):
If there's one thing we've learned from past biotech
cycles, it's this. Platforms win.
They take longer to build. They don't always look flashy,
but when they work, they work inscale and protolix.
It has a working platform, FDA approved products and a pipeline
built for precision. PLX is trading at just $2.48.

(27:06):
But the fundamentals say something else.
A company with revenue, with no debt, with positive cash flow,
with commercial stage drugs and a pipeline that fits the macro
trend. That's not speculative, that's
mispriced. And that mispricing creates your
edge. Our 12 month target is 6
dollars, 140% upside. Our five year target is $20 and

(27:30):
8X return. Can things go wrong?
Of course. But with a risk reward ratio
near 4 to one, the math works and so does the story.
So if you've been watching biotech from the sidelines, this
is your moment. Biotech is back, rare disease is
in, and Protolix sits right at the intersection.
The question is, will you wait for Wall Street to tell you it's

(27:53):
real, or will you move while it's still quiet?
Because this is where convictionlives in the gaps between value
and narrative, in the companies that execute quietly, and in the
investors who act before the crowd shows up.
If you want to stay ahead of these global shifts, don't just
listen, take action. Subscribe now on Apple Podcasts

(28:15):
and Spotify. Follow us on Twitter for real
time alerts and market threads divedeeperwithourfulllineupfinance.front[e-mail].
And if you're already following us, share this episode with a
friend who actually invests withstrategy.

(28:35):
And sign up for our newsletter to get exclusive insights,
breaking financial news and expert analysis delivered
straight to your inbox. Now for the disclaimer.
The information provided in thisepisode is for informational
purposes only. Investing involves risk,
including the potential loss of capital.
Always conduct your own due diligence and consult with a

(28:55):
licensed financial advisor before making decisions.
While we've highlighted opportunities like Protofix
Biotherapeutics ticker symbol PLX, this episode does not
provide personalized investment advice.
Past performance is not indicative of future results and
markets can change quickly. We may hold positions and some
of the companies discussed. Transparency is important, so

(29:17):
always verify information and base your decisions on personal
goals and risk tolerance. The music in this episode is
licensed under standard agreements.
Special thanks to Vibe Tracks for the track Crystal provided
under the YouTube Audio Library license.
This episode is copyright 2025 by Finance Frontier AI.

(29:38):
All rights reserved. Unauthorized reproduction or
distribution is strictly prohibited.
Thanks for joining us today. Stay strategic, stay focused and
take action. We'll see you next time.